779 patents
Page 10 of 39
Utility
Stable Aqueous Anti-tfpi Antibody Formulation
2 Feb 23
The present invention relates to the field of pharmaceutical formulations of antibodies.
Thomas Joseph Crowley, Robert Lee Dufield, Jennifer Juneau
Filed: 10 Nov 20
Utility
Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
31 Jan 23
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Filed: 19 Feb 21
Utility
Anti-GDF15 antibodies, compositions and methods of use
31 Jan 23
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
Kevin Charles Beaumont, Danna M. Breen, Matthew Allister Lambert, Jeffrey Raymond Chabot, Tao He, Ksenya Shchors, James R. Apgar
Filed: 15 Aug 19
Utility
HER2 Mutation Inhibitors
26 Jan 23
Mark Laurence BOYS, Bryan Daniel ELLIS, John Joseph GAUDINO, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK
Filed: 29 Jun 21
Utility
PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions
26 Jan 23
Meng Li, Anthony William Tolcher
Filed: 4 Jan 21
Utility
Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors
24 Jan 23
Joseph Walter Strohbach, Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Rubben Federico Torella, Yasheen Zhou, Thean Yeow Yeoh
Filed: 28 Oct 20
Utility
Compostions and Methods for Nucleic Acid Transfection Using Cationic Polymers and Stabilizers
19 Jan 23
Provided are compositions and methods for stabilizing a transfection cocktail containing DNA-cationic polymer complexes for an extended time, while maintaining high transfection efficiency.
Saurabh Kant Bhardwaj, Chia Hung Chu
Filed: 16 Dec 20
Utility
Melanocortin 4 Receptor Antagonists and Uses Thereof
19 Jan 23
Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
Filed: 8 Jun 21
Utility
PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL and PYRROLO[2,3-D]PYRIDINYL Acrylamides
12 Jan 23
The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof.
Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
Filed: 4 Aug 21
Utility
PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
12 Jan 23
Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
Filed: 15 Jul 21
Utility
KRas G12C inhibitors
10 Jan 23
The present invention relates to compounds that inhibit KRas G12C.
Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P Fischer, Aaron Craig Burns
Filed: 30 Jun 20
Utility
Escherichia Coli Compositions and Methods Thereof
5 Jan 23
In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof.
Annaliesa Sybil Anderson, Ye Che, Wei Chen, Laurent Oliver Chorro, Ling Chu, Robert G.K. Donald, Matthew Curtis Griffor, Jianxin Gu, Zeqiang Guan, Jin-Hwan Kim, Srinivas Kodali, Scott Ellis Lomberk, Jason Arnold Lotvin, Nishith Merchant, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, David Robert Stead, Karen Kiyoko Takane
Filed: 28 Oct 20
Utility
Tricyclic Compounds and Their Use As Phosphodiesterase Inhibitors
5 Jan 23
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
Filed: 12 Aug 22
Utility
Antibodies Specific for CD70 and Their Uses
5 Jan 23
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70).
Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
Filed: 1 Jun 22
Utility
Nitrile-containing antiviral compounds
3 Jan 23
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 17 Dec 21
Utility
Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
3 Jan 23
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution.
James Joseph Hussey, Andrew Gilbert Bright
Filed: 20 Aug 18
Utility
BCKDK inhibitors
3 Jan 23
Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
Filed: 26 Jun 20
Utility
Compositions relating to a mutant clostridium difficile toxin and methods thereof
27 Dec 22
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
Filed: 5 Dec 19
Utility
Azalactam Compounds as HPK1 Inhibitors
22 Dec 22
Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
Filed: 30 Apr 21
Utility
Neisseria Meningitidis Compositions and Methods Thereof
22 Dec 22
Annaliesa Sybil Anderson, John Lance Perez, Kathrin Ute Jansen, Paul Liberator, Cuiwen Tan, Thomas Richard Jones, Johannes Frederik Beeslaar, Judith Absalon, Jason Douglas Maguire, Shannon Lea Harris
Filed: 24 Sep 20